These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 9397296)

  • 1. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal protection in diabetes: an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    J Hypertens Suppl; 1996 Nov; 14(4):S21-5. PubMed ID: 8986939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium antagonists and the diabetic hypertensive patient.
    Parving HH; Rossing P
    Am J Kidney Dis; 1993 Jun; 21(6 Suppl 3):47-52. PubMed ID: 8503435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus.
    Parving HH
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S19-24. PubMed ID: 1382160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L; Rossing P; Jensen C; Hansen BV; Parving HH
    Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity.
    Baba T; Ishizaki T
    Drugs; 1992 Apr; 43(4):464-89. PubMed ID: 1377114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
    Baba T; Neugebauer S; Watanabe T
    Drugs; 1997 Aug; 54(2):197-234. PubMed ID: 9257079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Converting enzyme inhibitors and calcium antagonists in the long-term treatment of hypertension in chronic renal failure.
    Lenz T; August P
    Wien Klin Wochenschr; 1990 May; 102(11):315-9. PubMed ID: 2195780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy.
    Kopf D; Schmitz H; Beyer J; Frank M; Bockisch A; Lehnert H
    Diabetes Nutr Metab; 2001 Oct; 14(5):245-52. PubMed ID: 11806464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic management of diabetic nephropathy.
    Vivian EM; Rubinstein GB
    Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
    Bakris GL; Weir MR; DeQuattro V; McMahon FG
    Kidney Int; 1998 Oct; 54(4):1283-9. PubMed ID: 9767545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.